Objective  To track and explore the current situation, hotspots and trends of pharmacoeconomics evaluation research in China.

Methods  The literature related to pharmacoeconomics evaluation researches were collected from Web of Science Core Collection, and bibliometrics was used to conduct a visual analysis of the publication year, institution, author, and keywords of the included literature.

Results  A total of 754 documents were included, including 722 papers and 32 reviews. Before 2008, there was a little publications on pharmacoeconomics evaluation research in China, and which has continued to rise in recent years. The top 3 journals in the number of publications are Frontiers in Pharmacology (n=33), Frontiers in Public Health (n=30), and Frontiers in Oncology (n=26). The 754 researches were cited 6 404 times in total, with an average of 8.9 times per article. The publishing institutions mainly include Sichuan University, The Chinese University of Hong Kong, Shanghai Jiao Tong University, Central South University, Sun Yat-sen University and other well-known universities. The author who published the most papers was Li Q. The top 5 keywords are cost effectiveness analysis (frequency=148), therapy (frequency=90), economic evaluation (frequency=77), management (frequency=71), chemotherapy (frequency=62). Research hotspots have progressed from the exploration of pharmacoeconomics evaluation methodology to focusing on clinical decision-making.

Conclusion  The study of pharmacoeconomics evaluation in China started relatively late, but developed rapidly. In the future, it is necessary to strengthen regional cooperation and exploration of clinical decision-making and other application levels.

1.刘国恩. 中国药物经济学评价指南及导读: 2015版[M]. 北京: 科学出版社, 2015. [Liu GE. China guideline for pharmacoeconomic evaluations and manual: 2015 edition[M]. Beijing: Science Press, 2015.] https://xueshu.baidu.com/usercenter/paper/show?paperid=7565b3fcbfb6083f8cff8b5ee32325bc&site=xueshu_se&hitarticle=1.

2.杜清云, 姜彩娥, 石芳, 等. 药物经济学成本-效果在临床路径给药方案中的作用探究[J]. 中国医院药学杂志, 2016, 36(4): 315-318. [Du QY, Jiang CE, Shi Fang, et al. Role of pharmacoeconomics cost-effectiveness in clinical pathway dosage regimen[J]. Chinese Journal of Hospital Pharmacy, 2016, 36(4): 315-318.] DOI: 10.13286/j.cnki.chinhosppharmacyj.2016.04.17.

3.Rudmik L, Drummond M. Health economic evaluation: important principles and methodology[J]. Laryngoscope, 2013, 123(6): 1341-1347. DOI: 10.1002/lary.23943.

4.Raftery J. Economic evaluation: an introduction[J]. BMJ, 1998, 316(7136): 1013-1014. DOI: 10.1136/bmj.316.7136.1013.

5.Chen CM. CiteSpace II: Detecting and visualizing emerging trends and transient patterns in scientific literature[J]. Journal of the American Society for Information Science and Technology, 2006, 57(3), 359-377. DOI: 10.1002/asi.20317.

6.Chen C. Science mapping: a systematic review of the literature[J]. Journal of Data and Information Science, 2017, 2 (2): 1-40. DOI: 10.1515/jdis-2017-0006.

7.刘世贤, 王凯旋, 窦蕾, 等. 国内外药物经济学评价研究的文献计量及可视化分析[J]. 中国医院药学杂志, 2021, 41(22): 2368-2374,2384. [Liu SX, Wang KX, Dou L, et al. Bibliometrics and visualization analysis of pharmacoeconomic evaluation research at home and abroad[J]. Chinese Journal of Hospital Pharmacy, 2021, 41(22): 2368-2374,2384.] DOI: 10.13286/j.1001-5213.2021.22.18.

8.李杰, 陈超美. CiteSpace: 科技文本挖掘及可视化(第三版)[M]. 北京: 首都经济贸易大学出版社, 2016. [Li J, Chen CM. CiteSpace: text mining and visualization in scientific literature (third Edition)[M]. Beijing: Capital University of Economics and Business Press, 2016.] https://xueshu.baidu.com/usercenter/paper/show?paperid=c02915c15974aad45aa42fdc085258f8&site=xueshu_se&hitarticle=1.

9.Zhai YK, Zhu WJ, Cai YL, et al. Clinical- and cost-effectiveness of telemedicine in type 2 diabetes mellitus: a systematic review and meta-analysis[J]. Medicine (Baltimore). 2014, 93(28): e312. DOI: 10.1097/MD.0000000000000312.

10.沈爱宗, 张善堂, 史天陆, 等. 国内药物经济学文献计量学分析[J]. 药物流行病学杂志, 2005, 14(3): 167-169. [Shen AZ, Zhang ST, Shi TL, et al. Bibliometric analysis of domestic pharmacoeconomics in China[J]. Chinese Journal of Pharmacoepidemiology, 2005, 14(3): 167-169.] DOI: 10.3969/j.issn.1005-0698.2005.03.015.

11.胡彦波, 于雷, 黄崇亚. 学术期刊国际影响力提升策略探析——以Frontiers出版集团系列期刊为例[J]. 传播与版权, 2021(4): 64-67. [Hu YB, Yu L, Huang CY. Analysis on the strategy of enhancing the international influence of academic journals——taking the series of journals of Frontiers Publishing Group as an example[J]. Communication and Copyright, 2021(4): 64-67.] DOI: 10.16852/j.cnki.45-1390/g2.2021.04.023.

12.闻丹岩. 整合学术资源和出版资源,提升数字化服务能力——Frontiers系列英文学术期刊出版实践带来的启示[J]. 中国编辑, 2012, (2): 63-65. [Wen DY. Integrate academic resources and publishing resources to improve digital service ability——enlightenment from the publishing practice of Frontiers series English academic journals[J]. Chinese Editors Journal, 2012, (2): 63-65.] CNKI:SUN:BJZG.0.2012-02-015.

13.Wan N, Zhang TT, Hua SH, et al. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC[J]. Cancer Med. 2020, 9(5): 1683-1693. DOI: 10.1002/cam4.2793.

14.Liao W, Huang J, Hutton D, et al. Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China[J]. J Med Econ. 2019, 22(4): 344-349. DOI: 10.1080/13696998.2019.1570221.